Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in Chicago, USA, on 14–16 November 2026, hosted by the American Heart Association.

Bringing together global leaders in cardiovascular science, this premier event showcases groundbreaking research, clinical innovations, and collaborative strategies to advance heart health worldwide.

Representing Richmond Pharmacology

  • Dr Jörg Taubel, Chief Executive Officer

We look forward to connecting with attendees to discuss Richmond’s expertise in:

  • Novel therapies and clinical trial strategies for cardiovascular disease
  • Biomarker-driven approaches to improve trial efficiency
  • Regulatory pathways for emerging treatments
  • Patient-centric recruitment and engagement strategies
  • Collaboration between academia, industry, and regulators

Connect With Us

If you are attending AHA Scientific Sessions 2026 and would like to explore partnership or development opportunities email us at:

📧 fasteranswers@richmondpharmacology.com

Latest news

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
Read more

Upcoming Event

ESC Congress 2026

28 - 31 August 2026
Richmond Pharmacology is pleased to attend the ESC Congress 2026 in Munich, Germany, on 28 - 31 August 2026.
View event